What Proton Intelligence does

Proton Intelligence is a Vancouver-based, privately held medtech company founded in 2020 that is developing the Continuous Potassium Monitoring (CKM) platform — a real-time, on-demand potassium monitoring wearable positioned as the first device of its kind capable of giving clinicians continuous K+ readings for patients at risk of hyperkalemia. The company's core technical proposition is a novel biosensor architecture that enables wearable, continuous measurement of blood potassium, addressing a clinical gap in which no on-demand K+ monitoring capability currently exists to guide hyperkalemia treatment. The company is co-founded by Sahan Ranamukha, PhD (CEO), a biomedical engineer, and Victor Cadarso, PhD (CSO), a physicist and biosensing expert, and is registered as Proton Intelligence Inc. in British Columbia, Canada.

The CKM platform targets two principal end-user segments: clinicians and healthcare providers managing patients with Chronic Kidney Disease (the primary cause of hyperkalemia, affecting 33% of adults over 65 and 3.7M+ Americans), and clinicians treating heart failure patients where hyperkalemia carries cardiac-arrest risk. The product is explicitly labeled an "investigational device," indicating the company is pre-commercial and pursuing regulatory clearance before broad market launch. The intended business model is hardware sales to enterprise healthcare buyers (hospitals, clinical facilities, and nephrology practices), with future potential expansion into at-home use cases for chronic-condition management.

Proton Intelligence is venture-backed at the seed stage, having closed a $6.95M financing round in December 2024 led by SOSV with participation from 15th Rock, Exor, LongeVC, Tenmile, Trampoline Venture Partners, and We Venture Capital. The company has built credibility through selection into multiple medtech and life-sciences accelerators, including IndieBio San Francisco Batch 12 (2022), MedTech Innovator's 2023 Accelerator, Creative Destruction Lab's Vancouver Health Stream, BoostVC's Tribe 18, and e@UBC's Hatch Venture Builder Program. Headcount is reported in the 11-50 range, consistent with an early-stage clinical-development team, and the company currently operates from a single Vancouver headquarters with no disclosed subsidiary structure or international footprint.

Name

Proton Intelligence

Legal name

Proton Intelligence Inc.

Website

https://protonintelligence.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Proton Intelligence develops a Continuous Potassium Monitoring (CKM) wearable — the first real-time, on-demand potassium biosensor — to help clinicians manage hyperkalemia in patients with Chronic Kidney Disease and heart failure.

Ownership category

akta.pro rank

Product category

Continuous Potassium Monitoring Wearables

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)

akta.pro secondary industry

Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring) (HLAHAKAK)

Keywords

• Continuous biomarker monitoring
• Potassium monitoring wearable
• Chronic kidney disease care
• Hyperkalemia management
• Medical wearable devices

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Continuous Potassium Monitoring Device: Medical device generating revenue through wearable hardware sales to healthcare systems and clinical facilities for continuous potassium monitoring in at-risk patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Proton Intelligence is developing a Continuous Potassium Monitoring (CKM) Platform — a real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease and cardio-kidney-metabolic conditions. The device delivers continuous potassium level data to enable safer, more precise management of hyperkalemia and unlocks life-saving treatments that cannot currently be deployed when patients have dangerous K+ levels.

Product overview

Proton Intelligence offers a single unified product — the Continuous Potassium Monitoring (CKM) Platform — which is a real-time, on-demand potassium monitoring wearable device. This platform is designed to enable clinicians to safely and precisely treat and manage patients with hyperkalemia and chronic kidney disease, unlocking life-saving treatments that cannot be deployed when patients have dangerous potassium levels.

Differentiator

Problem solved

Functional benefit

Products and services

• Continuous Potassium Monitoring (CKM) Platform A real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease, hyperkalemia, and cardio-kidney-metabolic conditions by providing continuous potassium level data.

Quantifiable outcome

• 3.7M+ Americans affected by hyperkalemia represent the addressable market for potassium monitoring technology

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• MedTech InnovatorcoreStrategic or Co-development Partner · 1 January 2023Member of MedTech Innovator's 2023 Accelerator program, providing mentorship, resources, and networking for early-stage medical technology companies developing innovative healthcare solutions.
• IndieBio San Francisco Batch 12coreStrategic or Co-development Partner · 1 January 2022Selected for IndieBio's San Francisco Batch 12 accelerator program, a prominent life sciences accelerator providing funding and support for biotech and medtech startups. Featured in TechCrunch coverage of the cohort.
• BoostVC Tribe 18minorStrategic or Co-development PartnerMember of BoostVC's Tribe 18 accelerator program, supporting early-stage companies in the healthcare and blockchain sectors.
• Creative Destruction Lab Vancouver Health StreamminorStrategic or Co-development PartnerParticipant in Creative Destruction Lab's Vancouver Health Stream, an accelerator program focused on scalable, seed-stage ventures with high-impact potential in health technology.
• e@UBC Hatch Venture Builder ProgramminorStrategic or Co-development PartnerParticipant in e@UBC's Hatch Venture Builder Program, supporting entrepreneurship at the University of British Columbia and providing resources for early-stage venture development.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Dexcom: Continuous glucose monitoring wearable leader. Directly comparable as a wearable continuous biomarker monitoring platform with recurring consumables revenue; serves as the most direct analogue for what Proton aims to build in potassium.
• Abbott Diabetes Care (FreeStyle Libre): CGM platform competing with Dexcom. Comparable wearable continuous biomarker business model and enterprise/payer commercialization playbook relevant to a future CKM go-to-market.
• RenalSense: Continuous urine output monitoring for critically ill and acute kidney injury patients. Closest direct functional analogue in renal continuous monitoring, addressing similar hospital workflows.

Broad incumbents

• Medtronic Diabetes: Broader medtech incumbent with diabetes and cardiac monitoring franchises. Relevant as a potential strategic acquirer and as a benchmark for an integrated patient-monitoring commercial machine.
• Outset Medical: Tablo hemodialysis system for kidney care. Comparable as a renal-care device company commercializing novel technology into nephrology workflows; relevant for sales-cycle and reimbursement lessons.
• Siemens Healthineers (Blood Gas / RAPIDPoint): Major diagnostic instrument maker including blood-gas/electrolyte analyzers used in clinical potassium measurement. Relevant as a benchmark for incumbent diagnostic adoption and a potential strategic acquirer.

Emerging players

• Nova Biomedical: Manufacturer of electrolyte and blood-gas analyzers (including potassium measurement). Comparable as a potassium-measurement technology competitor in clinical settings, though primarily bench-top rather than wearable.
• Quanta Dialysis Technologies: Compact hemodialysis system developer. Comparable as a venture-backed medtech commercializing innovative renal-care technology into clinical workflows with similar reimbursement and adoption dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/protonintelligence

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proton Intelligence